Journal Front Page

News & Events

  • Call for Article for January Issue
  • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 25 December, 2017 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com
  • October 2017 issue published
  • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 6, Issue 4 (October Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • ICV
  • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level
  • AJPER Impact facor
  • It is to pleasure that Ajper SJIF imact facor has increse from 3.203 to 4.101. Also global impact factor incresed from 0.654 to 0.765.


Efficacy and Safety of Resveratrol as an Adjuvant Therapy in Patients with Dyslipidemia: Result of a Randomized Active Controlled Clinical Study

Rakesh Ojha1*, Pranesh Kulkarni 2, Bhavin Vyas 1

1Department of Pharmacology, Maliba College of Pharmacy, Uka Tarsadia University,
Bardoli, Surat, Gujarat, India.
2Vikas Hospital, Rambaug, Kalyan (West), Maharashtra, India


The aim of this study was to investigate the efficacy and safety of resveratrol as an adjuvant therapy in newly diagnosed dyslipidemic patients. In this randomized active-controlled study, dyslipidemic patients(male/female) aged 20-65 years were randomized to receive atorvastatin 10 mg or atorvastatin 10 mg plus resveratrol 1 gram daily for 12 months. Efficacy variables included change inlipid profile (total cholesterol [TC], serum triglycerides [TGA], low-density lipoprotein [LDL] and high-density lipoprotein [HDL]) from baseline and were followed-up for every 3 months. Treatment-emergent adverse events (TEAEs) were assessed. A total of 60 dyslipidemicpatients were analyzed (atorvastatin [n=30] andatorvastatin plus resveratrol [n=30]). Resveratrol as an adjuvant withatorvastatin significantly reduced plasma TC, TGA and LDL as compared to atorvastatin monotherapy (p<0.001 for eachparametre). Meanlevels of HDL were significantly higherin atorvastatin plus resveratrol group than atorvastatin (p<0.001). Both the study drugs have similar safety profile, and found well tolerable.

Keywords: Dyslipidemia; Resveratrol; Lipid profile; Atorvastatin

[Full Text Article]